Open Journal Systems
A review on drug-drug interactions and its risk factors in medical intensive care unit
To review the studies on Drug-Drug interactions , its risk factors in Intensive Care Unit (ICU) patients, the prevalence of Potential Drug-Drug Interactions(PDDIs)and levels of severity of PDDIs.
In this review article, a total of 10 literature studies were reviewed for prevalence of PDDIs and DDIs in ICU patients and other departments of different hospital settings. PDDIs are more prevalent in ICU patients than in other departments. The number of PDDIs increase with increase in number of drugs administered ranging from 9.8% for 2 drugs to 88.3% for 8 or more drugs. PDDIs also increase with prolonged hospital stay, presence of co-morbidities, increased age. The interaction between anti-coagulant and anti-platelet agents is responsible for greatest number of serious reactions and deaths or may prolong the length of hospital stay. Most of the identified DDIs are of moderate severity. A study compared baseline period when clinical pharmacist services were not provided with period when each patient’s profile was reviewed daily and interactions were minimized.
Most of the Drug-Drug interactions occur due to lack of knowledge regarding their Adverse Drug Reactions (ADRs) .The chances of occurrence of contraindicated DDIs should be minimized to prevent ADRs. Awareness of most commonly occurring DDIs should be raised by utilization of DDI guides clinical practice which can help prescribers and pharmacist to prevent DDI related ADRs.
Getachew H, Assen M, Dula F, Bhagavathula AS. Potential drug–drug interactions in pediatric wards of Gondar University Hospital, Ethiopia: A cross sectional study. Asian Pacific Journal of Tropical Biomedicine. 2016 Jun 1;6(6):534-8.
Janković SM, Pejčić AV, Milosavljević MN, Opančina VD, Pešić NV, Nedeljković TT, Babić GM. Risk factors for potential drug-drug interactions in intensive care unit patients. Journal of critical care. 2018 Feb 1;43:1-6.
Doubova SV, Reyes-Morales H, del Pilar Torres-Arreola L, Suárez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC health services research. 2007 Dec;7(1):147.
Ismail M, Khan F, Noor S, Haider I, Haq IU, Ali Z, Shah Z, Hassam M. Potential drug–drug interactions in medical intensive care unit of a tertiary care hospital in Pakistan. International journal of clinical pharmacy. 2016 Oct 1;38(5):1052-6.
Murtaza G, Khan MY, Azhar S, Khan SA, Khan TM. Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharmaceutical Journal. 2016 Mar 1;24(2):220-5.
Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug–drug interactions in Regione Emilia‐Romagna, Italy. Journal of clinical pharmacy and therapeutics. 2008 Apr 1;33(2):141-51.
Bucşa C, Farcaş A, Cazacu I, Leucuta D, Achimas-Cadariu A, Mogosan C, Bojita M. How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients?. European journal of internal medicine. 2013 Jan 1;24(1):27-33.
Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. Journal of critical care. 2011 Feb 1;26(1):104.e1-6.
Alvim MM, Silva LA, Leite IC, Silvério MS. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital. RevistaBrasileira de terapiaintensiva. 2015 Dec;27(4):353-9.
Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A. Identifying adverse drug reactions associated with drug-drug interactions. Drug safety. 2010 Aug 1;33(8):667-75.